- Home
- TRP vs ARGX Comparison
TRP vs ARGX Comparison
Compare TRP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRP
- ARGX
- Stock Information
- Founded
- TRP 1951
- ARGX 2008
- Country
- TRP Canada
- ARGX Netherlands
- Employees
- TRP N/A
- ARGX N/A
- Industry
- TRP
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRP
- ARGX Health Care
- Exchange
- TRP Nasdaq
- ARGX Nasdaq
- Market Cap
- TRP 49.3B
- ARGX 39.6B
- IPO Year
- TRP N/A
- ARGX 2017
- Fundamental
- Price
- TRP $52.07
- ARGX $711.43
- Analyst Decision
- TRP Hold
- ARGX Strong Buy
- Analyst Count
- TRP 3
- ARGX 18
- Target Price
- TRP $62.00
- ARGX $758.59
- AVG Volume (30 Days)
- TRP 1.5M
- ARGX 379.0K
- Earning Date
- TRP 07-31-2025
- ARGX 10-30-2025
- Dividend Yield
- TRP 4.80%
- ARGX N/A
- EPS Growth
- TRP 23.31
- ARGX N/A
- EPS
- TRP 2.99
- ARGX 18.75
- Revenue
- TRP $10,486,413,556.00
- ARGX $3,120,821,000.00
- Revenue This Year
- TRP $11.99
- ARGX $77.61
- Revenue Next Year
- TRP $5.28
- ARGX $30.50
- P/E Ratio
- TRP $17.42
- ARGX $33.77
- Revenue Growth
- TRP 15.85
- ARGX 88.04
- 52 Week Low
- TRP $40.79
- ARGX $510.06
- 52 Week High
- TRP $52.26
- ARGX $716.62
- Technical
- Relative Strength Index (RSI)
- TRP 66.98
- ARGX 73.06
- Support Level
- TRP $50.36
- ARGX $697.91
- Resistance Level
- TRP $52.10
- ARGX $710.00
- Average True Range (ATR)
- TRP 0.71
- ARGX 11.96
- MACD
- TRP 0.05
- ARGX 2.40
- Stochastic Oscillator
- TRP 92.80
- ARGX 94.25
About TRP TC Energy Corporation
TC Energy operates natural gas, oil, and power generation assets in Canada and the United States. The firm operates more than 60,000 miles of oil and gas pipelines, more than 650 billion cubic feet of natural gas storage, and about 4,300 megawatts of electric power.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.